Elias Sayour, MD, PhD
Stop Children's Cancer/Bonnie R. Freeman Professor For Pediatric Oncology Research; Assistant Dean
Department:
MD-NEUROLOGICAL SURGERY
Business Phone:
(352) 273-9000
Business Email:
elias.sayour@neurosurgery.ufl.edu
About Elias Sayour
Elias Sayour, MD, PhD, is the Stop Children’s Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research in the UF departments of neurosurgery and pediatrics at the University of Florida. He is also a principal investigator of the ribonucleic acid engineering laboratory at the Preston A. Wells, Jr. Center for Brain Tumor Therapy. He received his bachelor’s degree from Fordham University, his medical degree from the University of Buffalo and his doctorate from Duke University.
He completed his residency in pediatrics at Cohen’s Children’s Medical Center in New York and his fellowship at Duke University Medical Center. During his fellowship training, he completed a two-year National Institutes of Health research fellowship in cancer biology and developmental therapeutics. His primary research focus is developing tumor RNA loaded nanocarriers to re-direct host immunity against pediatric brain tumors.
Dr. Sayour is an NIH-funded investigator focused on on developing new nanotech vaccines to reprogram the immune system against cancer cells. He is investigating the use of personalized nanoparticles small enough to deliver essential information to the immune system educating it reject pediatric cancer. Currently his group is investigating the safety and efficacy of this novel vaccine formulation in canines with malignant brain tumors before translation into dedicated human studies.
Dr. Sayour’s work has been nationally recognized by the American Society of Pediatric Hematology-Oncology, National Institutes of Health, and U.S. Department of Defense. He has been the recipient of the Hyundai Hope on Wheels Hope Award, St. Baldrick’s Scholar Award, and the American Brain Tumor Association Discovery Award.
Dr. Sayour is board-certified in general pediatrics and pediatric hematology-oncology.
He has presented his work at several national meetings and is a member of the Children’s Oncology Group, Society of Neuro-Oncology and the American Society of Pediatric Hematology-Oncology.
Teaching Profile
Courses Taught
2020-2024
GMS6847 Translational Research and Therapeutics: Bench, Bedside, Community, & Policy
2017-2024
GMS6065 Fundamentals of Cancer Biology
2018
MDT7400 Elect Top/Pediatrics
2018
MDC7400 Pediatric Clerkship
2018
BME7980 Research for Doctoral Dissertation
2021-2022
MDU4001 Introduction to Medical Science Seminar 1
2022
GMS6251 Molecular Therapy I ? Vectors and Molecular Mechanisms
2023-2024
GMS6905 Independent Studies in Medical Sciences
Board Certifications
-
Hematology-OncologyAmerican Board of Pediatrics
-
PediatricsAmerican Board of Pediatrics
Clinical Profile
Specialties
- Neurosurgery
- Pediatrics
Subspecialties
- Pediatric Hematology-Oncology
Areas of Interest
- Brain tumor – children
Research Profile
Areas of Interest
- Immunotherapeutics for CNS malignancies
- Pediatric brain tumors
Open Researcher and Contributor ID (ORCID)
0000-0002-5309-3197
Publications
2024
Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen-presenting cells.
Molecular therapy. Methods & clinical development.
32(1)
[DOI] 10.1016/j.omtm.2024.101192.
[PMID] 38327807.
2024
Vaccines: a promising therapy for myelodysplastic syndrome.
Journal of hematology & oncology.
17(1)
[DOI] 10.1186/s13045-023-01523-4.
[PMID] 38191498.
2023
Association of Suppressive Myeloid Cell Enrichment with Aggressive Oropharynx Squamous Cell Carcinoma.
Cancers.
15(8)
[DOI] 10.3390/cancers15082346.
[PMID] 37190274.
2023
Bioconjugated liquid-like solid enhances characterization of solid tumor – chimeric antigen receptor T cell interactions
Acta Biomaterialia.
172:466-479
[DOI] 10.1016/j.actbio.2023.09.042.
2023
Bioconjugation of COL1 protein on liquid-like solid surfaces to study tumor invasion dynamics
Biointerphases.
18(2)
[DOI] 10.1116/6.0002083.
[PMID] 36898958.
2023
Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies.
Journal of applied statistics.
50(9):2055-2078
[DOI] 10.1080/02664763.2022.2105827.
[PMID] 37378271.
2023
mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.03.18.532056.
[PMID] 36993158.
2023
Spotlighting cellular therapies to advance the treatment of medulloblastoma.
Neuro-oncology.
25(4):628-630
[DOI] 10.1093/neuonc/noad005.
[PMID] 36629263.
2023
Three-Dimensional Bioconjugated Liquid-Like Solid (LLS) Enhance Characterization of Solid Tumor – Chimeric Antigen Receptor T cell interactions.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.02.17.529033.
[PMID] 36865164.
2023
Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology.
Neoplasia (New York, N.Y.).
42
[DOI] 10.1016/j.neo.2023.100909.
[PMID] 37244226.
2022
CAR T Cell Locomotion in Solid Tumor Microenvironment.
Cells.
11(12)
[DOI] 10.3390/cells11121974.
[PMID] 35741103.
2022
Contemporary RNA Therapeutics for Glioblastoma
NeuroMolecular Medicine.
24(1):8-12
[DOI] 10.1007/s12017-021-08669-9.
[PMID] 34101090.
2022
Evolution and Revolution of Imaging Technologies in Neurosurgery.
Neurologia medico-chirurgica.
62(12):542-551
[DOI] 10.2176/jns-nmc.2022-0116.
[PMID] 36288973.
2022
Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1)
Neoplasia.
31
[DOI] 10.1016/j.neo.2022.100813.
[PMID] 35834946.
2022
The current landscape of immunotherapy for pediatric brain tumors.
Nature cancer.
3(1):11-24
[DOI] 10.1038/s43018-021-00319-0.
[PMID] 35121998.
2021
Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Veterinary immunology and immunopathology.
232
[DOI] 10.1016/j.vetimm.2020.110169.
[PMID] 33387703.
2021
GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction
Translational Oncology.
14(2)
[DOI] 10.1016/j.tranon.2020.100971.
[PMID] 33321428.
2021
Nanoparticles as immunomodulators and translational agents in brain tumors
Journal of Neuro-Oncology.
151(1):29-39
[DOI] 10.1007/s11060-020-03559-9.
2021
Optimizing T Cell-Based Therapy for Glioblastoma.
Frontiers in immunology.
12
[DOI] 10.3389/fimmu.2021.705580.
[PMID] 34421912.
2020
Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma.
Cancer research.
80(3):499-509
[DOI] 10.1158/0008-5472.CAN-19-1577.
[PMID] 31723000.
2020
GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas.
American journal of cancer research.
10(2):674-687
[PMID] 32195035.
2019
Characterization of myeloid-derived suppressor cells and cytokines GM-CSF, IL-10 and MCP-1 in dogs with malignant melanoma receiving a GD3-based immunotherapy.
Veterinary immunology and immunopathology.
216
[DOI] 10.1016/j.vetimm.2019.109912.
[PMID] 31446208.
2019
CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Nature communications.
10(1)
[DOI] 10.1038/s41467-019-11869-4.
[PMID] 31488817.
2019
Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.
ACS nano.
13(12):13884-13898
[DOI] 10.1021/acsnano.9b05037.
[PMID] 31730332.
2019
Emerging trends in immunotherapy for pediatric sarcomas.
Journal of hematology & oncology.
12(1)
[DOI] 10.1186/s13045-019-0756-z.
[PMID] 31311607.
2019
Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Neuro-oncology.
21(6):730-741
[DOI] 10.1093/neuonc/noz015.
[PMID] 30668768.
2019
RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.
Molecular therapy : the journal of the American Society of Gene Therapy.
27(4):837-849
[DOI] 10.1016/j.ymthe.2018.10.007.
[PMID] 30448196.
2019
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling.
Journal for immunotherapy of cancer.
7(1)
[DOI] 10.1186/s40425-019-0809-4.
[PMID] 31753028.
2018
Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes.
International journal of molecular sciences.
19(10)
[DOI] 10.3390/ijms19102890.
[PMID] 30249040.
2018
CD70, a novel target of CAR T-cell therapy for gliomas.
Neuro-oncology.
20(1):55-65
[DOI] 10.1093/neuonc/nox116.
[PMID] 28651374.
2018
Infiltrative and drug-resistant slow-cycling cells support metabolic heterogeneity in glioblastoma.
The EMBO journal.
37(23)
[DOI] 10.15252/embj.201798772.
[PMID] 30322894.
2018
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy
Nano Letters.
18(10):6195-6206
[DOI] 10.1021/acs.nanolett.8b02179.
[PMID] 30259750.
2018
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.
Frontiers in molecular neuroscience.
11
[DOI] 10.3389/fnmol.2018.00082.
[PMID] 29643764.
2017
CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression.
Frontiers in immunology.
8
[DOI] 10.3389/fimmu.2017.01451.
[PMID] 29163521.
2017
Immunotherapy for Pediatric Brain Tumors.
Brain sciences.
7(10)
[DOI] 10.3390/brainsci7100137.
[PMID] 29065490.
2017
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines
Journal of Immunology Research.
2017:1-7
[DOI] 10.1155/2017/3145742.
[PMID] 28265580.
2017
Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.
Oncoimmunology.
6(1)
[DOI] 10.1080/2162402X.2016.1256527.
[PMID] 28197373.
2017
The effects of new or worsened postoperative neurological deficits on survival of patients with glioblastoma.
Journal of neurosurgery.
127(1):123-131
[DOI] 10.3171/2016.7.JNS16396.
[PMID] 27689459.
2017
Translational nanoparticle engineering for cancer vaccines.
Oncoimmunology.
6(10)
[DOI] 10.1080/2162402X.2017.1290036.
[PMID] 29123947.
2016
Bone marrow transplantation for CVID-like humoral immune deficiency associated with red cell aplasia.
Pediatric blood & cancer.
63(10):1856-9
[DOI] 10.1002/pbc.26092.
[PMID] 27273469.
2016
Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
22(3):582-95
[DOI] 10.1158/1078-0432.CCR-15-0713.
[PMID] 26405194.
2016
FGFR1 N546K and H3F3A K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers.
Histopathology.
69(4):704-7
[DOI] 10.1111/his.12983.
[PMID] 27061725.
2016
Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.
Cancer immunology, immunotherapy : CII.
65(2):205-11
[DOI] 10.1007/s00262-015-1784-3.
[PMID] 26759007.
2015
A novel ELANE gene mutation in a patient with severe congenital neutropenia and intermittent thrombocytopenia.
Pediatric blood & cancer.
62(10):1870-1
[DOI] 10.1002/pbc.25528.
[PMID] 25882539.
2015
Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics.
Journal for immunotherapy of cancer.
3
[DOI] 10.1186/s40425-015-0058-0.
[PMID] 25901285.
2015
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
Cancer immunology, immunotherapy : CII.
64(4):419-27
[DOI] 10.1007/s00262-014-1651-7.
[PMID] 25555571.
2015
Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.
Oncoimmunology.
4(3)
[PMID] 25949916.
2015
Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
Cancer immunology research.
3(4):320-5
[DOI] 10.1158/2326-6066.CIR-14-0100.
[PMID] 25387895.
2014
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
PloS one.
9(4)
[DOI] 10.1371/journal.pone.0094281.
[PMID] 24722266.
2013
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer immunology, immunotherapy : CII.
62(6):983-7
[DOI] 10.1007/s00262-013-1405-y.
[PMID] 23591978.
Grants
Apr 2024
ACTIVE
Targeting Glycogen Metabolism in Ewing's Sarcoma: Diagnostic, Prognostic, and Therapeutic Applications
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Feb 2024
ACTIVE
RNA-nanoparticle (RNA-NP) vaccine for ARMS
Role: Other
Funding: KATE AMATO FOUNDATION
Jul 2023
ACTIVE
Nanoparticle vaccines targeting metastatic osteosarcoma
Role: Principal Investigator
Funding: OSTEOSARCOMA INSTITUTE
Jul 2023
ACTIVE
Studying the impact of RNA-nanoparticle vaccine on immune response to DIPG/DMG
Role: Other
Funding: DIPG DMG RESEARCH FUNDING ALLIANCE
Jul 2023
ACTIVE
Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)
Role: Other
Funding: STANFORD UNIV
via NATL INST OF HLTH NIDDK
Jun 2023
ACTIVE
UF Health Cancer Center Support Grant
Role: Other
Funding: NATL INST OF HLTH NCI
Apr 2023
ACTIVE
Phase I/II clinical trial for malignant pediatric gliomas using 8R-70CAR T cells
Role: Co-Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Feb 2023
ACTIVE
An RNA-based nanoparticle vaccine approach for the prevention and treatment of C9orf72 ALS/FTD
Role: Co-Project Director/Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Jan 2023
ACTIVE
Phase I trial of multilamellar mRNA lipid particles for recurrent pediatric high-grade glioma
Role: Principal Investigator
Funding: ALEXS LEMONADE STAND FOUNDATION
Jan 2023
ACTIVE
Investigating the Immune Response to RNA-lipid Nanoparticle Vaccines in a Clinical Trial for Canines with Osteosarcoma
Role: Other
Funding: PEDIATRIC CANCER RESEARCH FOU
Dec 2022
ACTIVE
Establishment of 3D metastatic osteosarcoma organoid model to accelerate combination immunotherapy
Role: Other
Funding: HYUNDAI HOPE ON WHEELS
Nov 2022
ACTIVE
Determining and enhancing stability of RNA-nanoparticle vaccines for a multi-center NPCF clinical trial for patients with metastatic osteosarcoma
Role: Other
Funding: NATL PEDIATRIC CANCER FOU
Sep 2022
ACTIVE
Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Aug 2022
ACTIVE
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 05/21/2020
Role: Principal Investigator
Funding: US FOOD AND DRUG ADMN
Jul 2022
ACTIVE
Leveraging RNA-lipid nanoparticle vaccines to induce immune response in metastatic pulmonary osteosarcoma
Role: Co-Investigator
Funding: THE V FOU FOR CANCER RESEARCH
May 2022
ACTIVE
Patterns of resistance to initial therapeutic treatment in Ewings Sarcoma
Role: Co-Investigator
Funding: Hematology/Oncology Pharmacy Asso Fou
Apr 2022
ACTIVE
Novel RNA-Nanoparticle vaccine for treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy
Role: Co-Investigator
Funding: FL DEPT OF HLTH BIOMED RES PGM/J&E KING
Apr 2022
ACTIVE
Unlocking CAR T cell efficacy against osteosarcoma using adjuvant RNA vaccine
Role: Other
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Feb 2022
ACTIVE
A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via PEDIATRIC BRAIN TUMOR FOUNDATION
Feb 2022
– Jun 2022
A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via LILABEAN FOUNDATION
Jan 2022
ACTIVE
Development of RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
Role: Principal Investigator
Funding: NATL PEDIATRIC CANCER FOU
Jan 2022
– Jun 2023
Development of RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via NATL PEDIATRIC CANCER FOU
Oct 2021
– Apr 2023
Pan-Neoantigen Targeted RNA-nanoparticles for Recurrent Pulmonary Osteosarcoma
Role: Principal Investigator
Funding: CHANCE FOR LIFE FOUNDATION
Sep 2021
ACTIVE
Immune correlate studies in pediatric high-grade glioma patients receiving RNA nanoparticle vaccines
Role: Principal Investigator
Funding: TEAM JACK FOUNDATION
Jul 2021
– Aug 2022
Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
Role: Principal Investigator
Funding: Rally Foundation
Apr 2021
ACTIVE
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis
Role: Co-Investigator
Funding: NATL INST OF HLTH NCI
Feb 2021
ACTIVE
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Feb 2021
ACTIVE
PNOC 021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via LILABEAN FOUNDATION
Jan 2021
ACTIVE
A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via BRISTOL MYERS SQUIBB CO
Jul 2020
ACTIVE
Pediatric Brain Tumor ConsortiumA multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors
Role: Principal Investigator
Funding: ST JUDE CHILDRENS RESEARCH HOSPITAL
via NATL INST OF HLTH NCI
Jul 2020
ACTIVE
RNA-nanoparticle vaccines for pediatric high-grade glioma
Role: Principal Investigator
Funding: CURESEARCH FOR CHILDRENS CANCER
Jul 2020
ACTIVE
Translating Personalized RNA Nanoparticle Vaccines for Oral Cancer
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Jul 2020
– Jul 2021
Remodeling Host Immunity in Oral Cancer with Personalized RNA Nanoparticle Vaccines
Role: Other
Funding: NATL INST OF HLTH NIDCR
Jun 2020
– Nov 2023
Novel immunologic therapy of soft tissue sarcoma
Role: Co-Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jun 2020
– Nov 2023
Multi-center phase I study evaluating lipid-nanoparticle vaccines against pediatric high-grade glioma
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jun 2020
– May 2023
Lipidnanoparticle vaccines targeting metastatic lung cancer from osteosarcoma
Role: Principal Investigator
Funding: FL DEPT OF HLTH BANKHEAD-COLEY CANCER RE
Jun 2020
ACTIVE
A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for
Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
Role: Principal Investigator
Funding: DANA FARBER CANCER INST
via DOT THERAPEUTICS-1
May 2020
– Jan 2022
A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
Dec 2019
– Jun 2022
Nanoparticles targeting genetic translocations in pediatric brain tumors
Role: Principal Investigator
Funding: HYUNDAI HOPE ON WHEELS
Sep 2019
ACTIVE
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
Role: Principal Investigator
Funding: ICON CLINICAL RESEARCH INC
via REGENERON PHARMACEUTICALS
Aug 2019
ACTIVE
A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intristic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via CANNONBALL KIDS CANCER FOUNDATION
Jul 2019
– Sep 2021
Immunotherapeutic targeting of osteosarcoma with nanoparticle vaccines
Role: Principal Investigator
Funding: Rally Foundation
Jul 2019
– Dec 2020
Re-programming immunity to target mutations across medulloblastoma subtypes
Role: Principal Investigator
Funding: ST BALDRICKS FOUNDATION
Jan 2019
– Dec 2023
Development of personalized RNA loaded nano particles for children with refractory solid tumors.
Role: Principal Investigator
Funding: UF FOUNDATION
Dec 2018
– Mar 2022
A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High Grade Glioma (Excluding Diffuse Intrinsic Pontine Glioma)
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via THE V FOU FOR CANCER RESEARCH
Jul 2018
ACTIVE
Florida Center for Brain Tumor Research
Role: Project Manager
Funding: FL DEPT OF HLTH
Jul 2018
– Dec 2021
Legacy Foundation
Role: Project Manager
Funding: UF FOUNDATION
Jul 2018
– Jun 2020
Host Immunomodulatory RNA-nanoparticles targeting malignant canine glioma
Role: Principal Investigator
Funding: UF FOUNDATION
Mar 2018
– Nov 2022
Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E – or BRAF Ins T mutant Brain Tumors
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via GENENTECH INC
Jan 2018
– Jun 2020
Development of Personalized RNA Loaded Nanoparticles for Children with Refractory Solid Tumors
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via NATL PEDIATRIC CANCER FOU
Dec 2017
ACTIVE
Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via PEDIATRIC LOW GRADE ASTROCYTOMA FOU
Nov 2017
ACTIVE
Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed
Pediatric High-grade Gliomas (Phase I)
Role: Principal Investigator
Funding: H LEE MOFFITT CANCER CTR & RES INST
via NATL PEDIATRIC CANCER FOU
Sep 2017
– Sep 2020
RNA-nanoparticles targeting H3.3 K27M epitopes in diffuse intrinsic pontine glioma
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Sep 2017
– Jun 2021
UFHCC Triple Negative Breast Cancer (TNBC) Pilot Project Program
Role: Project Manager
Funding: MULTIPLE SPONSORS
Jul 2017
– Dec 2019
Immunotherapeutic targeting of osteosarcoma neoantigens
Role: Principal Investigator
Funding: Rally Foundation
May 2017
– Feb 2023
Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Apr 2017
– Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Nov 2016
ACTIVE
Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single-Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
Role: Principal Investigator
Funding: NATIONWIDE CHILDRENS HOSPITAL
Sep 2016
ACTIVE
A Clinical and Molecular Risk-directed Therapy for Newly Diagnosed Medulloblastoma
Role: Principal Investigator
Funding: ST JUDE CHILDRENS RESEARCH HOSPITAL
Sep 2016
– Aug 2021
Harnessing the Immunologic Capacity of RNA-nanoparticle Vaccines Targeting Glioblastoma
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jul 2016
– Jun 2020
Re-programming immunity to target mutations across medulloblastoma subtypes
Role: Principal Investigator
Funding: ST BALDRICKS FOUNDATION
Jul 2016
– Jun 2020
RNA nanoparticle vaccines targeting malignant canine gliomas
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Apr 2016
– Mar 2018
Re-programming osteosarcoma immune evasion with CAR modified T cells
Role: Principal Investigator
Funding: UF FOUNDATION
Jul 2015
ACTIVE
Florida Academic Cancer Center Alliance Seed Grants
Role: Project Manager
Funding: UF HEALTH SHANDS HOSPITAL
Dec 2014
– Jun 2017
Efficacious, Translational and Personalized RNA-nanoparticle Vaccines Targeting Pediatric Brain Tumors
Role: Principal Investigator
Funding: HYUNDAI HOPE ON WHEELS
Jul 2013
– Jun 2021
Florida Center for Brain Tumor Research – Statewide Brain Tumor Registry Program at the McKnight Brain Institute
Role: Project Manager
Funding: FL DEPT OF HLTH
Education
Fellowship – Pediatric Hematology/Oncology
2013
·
Duke University Medical Center
Ph.D.
2012-2015
·
Duke University
Residency – Pediatrics
2010
·
Long Island Jewish Medical Center
M.D.
2007
·
University at Buffalo
B.S.
2003
·
Fordham University
Contact Details
Phones:
- Business:
- (352) 273-9000
Emails:
- Business:
- elias.sayour@neurosurgery.ufl.edu
Addresses:
- Business Mailing:
-
PO BOX 100265
PO BOX 100265
DEPARTMENT OF NEUROSURGERY
GAINESVILLE FL 326100265 - Business Street:
-
L2-100
1149 Newell Dr.
GAINESVILLE FL 32611